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Background: Since 2010, World Health Organization (WHO) guidelines discourage using stavudine in first-line
regimens due to frequent and severe side effects. This study describes the implementation of this recommendation
and trends in usage of antiretroviral therapy combinations in a cohort of HIV-positive patients in rural Tanzania.
Methods: We analyzed longitudinal, prospectively collected clinical data of HIV-1 infected adults initiating antiretroviral
therapy within the Kilombero Ulanga Antiretroviral Cohort (KIULARCO) in Ifakara, Tanzania from 2007-2011.
Results: This analysis included data of 3008 patients. Median age was 38 (interquartile range [IQR] 31-45) years, 1962
(65.2%) of all subjects were female, and median CD4+ cell count at enrollment was 168 cells/mm3 (IQR 81-273). The
percentage of prescriptions containing stavudine in initial regimens fell from a maximum of 75.3% in 2008 to 10.7% in
2011. TDF/FTC/EFV became available in 2009 and was used in 41.9% of patients initiating cART in 2011. An overall
on-treatment analysis revealed that d4T/3TC/NVP and AZT/3TC/EFV were the most prescribed combinations in each
year, including 2011 (674 [36.5%] and 641 [34.7%] patients, respectively). Of those receiving stavudine in 2011, 659
(89.1%) initiated it before 2011.
Conclusions: Initial cART with stavudine declined to low levels according to recommendations but the overall use of
stavudine remained substantial, as individuals already on cART containing stavudine were not changed to alternative
drugs. Our findings highlight the critical need to exchange stavudine in treatment regimens of patients who initiated
therapy in earlier years.
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The revision of the World Health Organization (WHO)
HIV treatment guidelines in 2010 brought several
changes to the management of HIV patients [1]. Among
them was a strong statement about progressing to less
toxic antiretroviral drugs in first-line regimens, i.e. dis-
couraging the use of stavudine in initial drug combina-
tions. This drug was crucial in rolling out combined
antiretroviral therapy (cART) in low-income setting as
in Sub-Saharan Africa (SSA) for its low price and good
efficacy in suppressing replication of HIV. However, se-
vere side effects associated with stavudine use, such as
peripheral neuropathy, lactic acidosis and lipodystrophy* Correspondence: fcfranzeck@gmail.com
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reproduction in any medium, provided the orhave been shown to be frequent and accumulating over
time in several African cohorts [2,3]. In the United
States, stavudine was already removed in 2004 from the
list of preferred first-line antiretroviral drugs recom-
mended by the US Department of Health and Human
Services (DHHS) [4].
The goal of phasing out stavudine still competes in
budgetary terms with other priorities in advancing cART
as direct drug costs of stavudine were still at around
50% compared to alternative regimens in 2011 [5]. Re-
cently, prices for generic formulations of more modern
pharmaceuticals such as tenofovir have declined sub-
stantially. This should assist efforts to achieve the WHO
goal of phasing out the use of stavudine containing regi-
mens. In some settings, replacing stavudine with tenofo-
vir or zidovudine was judged cost-effective [6-8] andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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be expected.
Many national HIV programs have consecutively adopted
the recommendations of the WHO, including the
National AIDS Control Program (NACP) of Tanzania:
In February 2009, the preferred regimen was changed
from d4T/3TC/NVP to AZT/3TC/EFV and TDF/FTC/
EFV was introduced as an alternative option [9]. How-
ever, d4T/3TC/NVP was still supported as a valid
first-line combination for patients with anemia initiating
therapy. No recommendation was issued to replace stavu-
dine in existing prescription if it was tolerated without oc-
currence of severe side effects.
In order to describe how recommendations issued by
the WHO eventually permeate to treating clinicians in
low-income countries, this study describes prescription
trends of antiretroviral therapy combinations in a large
cohort of HIV patients in rural Tanzania over a five-year
period.
Methods
We analysed data of HIV-1 infected adults (≥ 18 years of
age) initiating cART within the Kilombero Ulanga Anti-
retroviral Cohort (KIULARCO) at the chronic disease
clinic at the St. Francis Referral Hospital in Ifakara. The
hospital is the most important health care facility in the
rural Kilombero and Ulanga Districts of the Morogoro
Region in Southern Tanzania, providing treatment and
care for a population of about 600,000 inhabitants. Demo-
graphic, clinical and laboratory data were prospectively
collected from consenting patients at each consultation at
the clinic. Medical doctors and clinical officers filled in
standardized paper forms which consecutively where
double entered into an electronic database (DMSys, Sig-
masoft, Illinois, USA). Treatment failure was defined clin-
ically or immunologically according to WHO criteria (50%
drop in CD4 count from peak value within 6 months, or
return to pre-ART baseline CD4 count or lower). Anti-
retroviral therapy combinations used for cases of treat-
ment failure are referred to as second-line treatment
regimens. Data collected from the 1st of January 2007
until the 31st of December 2011 were included in the
analysis. In case a subject received > 1 regimen in one
calendar year, all combinations prescribed during that
year were included in the overall prescription analysis.
Patients who initiated cART before 2007 were included
in the overall prescription analysis. There was no active
tracking mechanism of patients lost to follow-up during
the study period. Continuous variables are expressed as
median (interquartile range) and frequencies (percentages)
for categorical variables. For calculation of p-values for
trend, a chi-square statistic for trend was used. All statis-
tical analyses were performed using Stata 11.2 (StataCorp,
Texas, USA).Ethical statement
All subjects included were given oral and written infor-
mation about the collection of their clinical data and
signed an informed consent form. Ethical approval was
granted by the local Ethical Committee of the Ifakara
Health Institute and the Medical Research Coordination
Committee of the National Institute of Medical Research
of Tanzania.
Results
Patients characteristics
This analysis included data of 3008 patients (Figure 1).
Of these, 2752 (91.5%) had >1 visit recorded, accumulat-
ing a total of 5085.2 person-years of follow-up. Median
time of follow-up was 1.5 (IQR 0.5-3.0) years. Of these
subjects, 1962 (65.2%) were female, median age at en-
rollment into care was 38 (interquartile range [IQR]
31-45) years and median CD4+ cell count was 168 (IQR
81-273) cells/μL (Table 1). Of the study population in-
cluded, 1162 patients (38.6%) were not followed until
the end of the study in 2011. Of these, 135 (11.6%) died,
197 (16.9%) were transferred to other treatment facilities
and 830 (71.4%) were lost to follow-up without indica-
tion of the cause (Figure 1). The number of patients
initiating cART per year was decreasing after 2009
(Table 2). This decline was temporally related to the
opening of alternative treatment facilities in the district
during the course of the study.
First-line regimen at cART initiation
From 2007 until the end of 2008, d4T/3TC/NVP and
AZT/3TC/EFV were the two major combinations used
as first-line regimens with proportions of 71.4% and
23.3% in 2008, respectively (Figure 2a, Table 2). A de-
cline of usage of stavudine was observed from 2009 on
and only 10.7% of all patients initiating a first-line regi-
men in 2011 received stavudine (p for trend <0.001).
This was compensated initially with increasing usage
of TDF/FTC/EFV and AZT/3TC/NVP. The number
of initial prescriptions of TDF/FTC/EFV increased rap-
idly after its introduction in 2009 to 41.9% by the end
of 2011. By 2011, the three most commonly used regi-
mens for initiating new patients on cART were TDF/
FTC/EFV (41.9%), AZT/3TC/EFV (33.3%) and AZT/
3TC/NVP (13.8%).
Overall cART regimen prescriptions
In every year of observation, d4T/3TC/NVP was the
most prescribed combination overall (Figure 2b, Table 3).
Still by 2011, 674 (36.5%) patients of this cohort were re-
ceiving this regimen but prescriptions were declining
from a maximum of 1080 (61.4%) since 2009 (p for
trend <0.001). Of those subjects receiving any d4T con-
taining combination in 2011, 659 (89.1%) were initiated
Figure 1 Flowchart of patient enrollment. The period of observation lasted from 1st of January 2007 until the 31st of December 2011. All
adult (≥ 18 years of age) patients initiating antiretroviral therapy at the study site giving informed consent were included in the analysis. No data
on the count of subjects declining informed consent was available.
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was AZT/3TC/EFV, usage of which increased until the
end of 2009 to 654 (37.2%) patients and then remained
on a constant level. In 2011, 641 (34.7%) of patients were
being treated with this combination. Total prescriptions
of TDF/FTC/EFV increased from 84 (4.8%) in 2009 to
600 (32.5%) in 2011.
There were significant differences in the percentage of
female and male patients receiving TDF/FTC/EFV in
the years 2009-2011. By 2011, only 29.4% of females
compared to 36.1% of males received this combination
(p = 0.005). On the other hand, the percentage of female
patients receiving the nevirapine containing regimens
d4T/3TC/NVP and AZT/3TC/NVP was higher than
those of male patients but these differences were notTable 1 Characteristics of study participants at
enrollment into care
Characteristic Value (n = 3008 )
Female sex 1962 (65.2%)
Age (years) 38 (31-45)
BMI (kg/m2) 20.3 (18-22.7)
WHO stage at enrollment † I 949 (31.6%)
II 776 (25.8%)
III 808 (26.9%)
IV 341 (11.3%)
CD4+ count (cells/μl) ‡ 168 (81-273)
† missing in 134 (4.4%) ‡ missing in 431 (14.3%).
Data are presented as count (column percentage) or median
(interquartile range).statistically significant (in 2011: 38.6% vs. 34%, p = 0.1 and
17.1% vs. 14.9%, p = 0.25, respectively). There was no differ-
ence of gender concerning AZT/3TC/EFV (2011: p = 0.82).
The ratio of second-line (i.e. treatment combinations
used in case of treatment failure) to total regimens
remained stable over time (p for trend = 0.13) with a
maximum of 33 (1.7%) patients in 2011. Of these, 31
(93.9%) received a combination of ABC/ddI/LPVr and 2
(6.1%) ABC/ddI/SQVr.
First-line treatment modifications
Over the whole period of observation, 242 of 1475
(16.4%) subjects receiving any regimen containing stavu-
dine at any point during their follow-up were changed
to alternative first-line combinations excluding stavudine
after a median of 1.0 (IQR 0.4-1.8) years. The most com-
mon replacement was a fixed dose combination of AZT/
3TC/NVP which accounted for 40% (97/242) of substi-
tutions overall (Table 4). TDF/FTC/EFV was progres-
sively selected as a replacement for stavudine after 2009
and was the subsequent regimen in 51.1% of all cases in
2011. This rise was mostly compensated by a decline of
substitutions to AZT/3TC/EFV, which decreased from
52.2% in 2008 to 7% in 2011. However in 104 cases,
stavudine was introduced to the treatment combinations
in patients who were not prescribed stavudine in the
preceding regimen.
Discussion
In this rural cohort of HIV-positive patients, modern
antiretroviral combinations have been adopted promptly
Table 2 Proportions of initial first-line regimens prescribed by calendar year
2007 2008 2009 2010 2011
(n = 630) (n = 741) (n = 753) (n = 467) (n = 411)
d4T/3TC/NVP 420 (66.7%) 529 (71.4%) 348 (46.2%) 91 (19.5%) 44 (10.7%)
d4T/3TC/EFV 24 (3.8%) 29 (3.9%) 25 (3.3%) 6 (1.3%) 0
AZT/3TC/NVP 8 (1.2%) 10 (1.2%) 5 (0.7%) 20 (4.3%) 57 (13.8%)
AZT/3TC/EFV 178 (28.3%) 173 (23.3%) 320 (42.5%) 154 (33.0%) 137 (33.3%)
TDF/FTC/EFV 0 0 55 (7.3%) 196 (42.0%) 173 (41.9%)
Data is presented as count (column percentage).
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guidelines. However, stavudine based combinations were
still the most used overall by the end of the year 2011
because 90% of patients who initiated therapy containing
stavudine before the update of guidelines in 2009 were
not changed to alternative regimens. During the study
period, two consecutive editions of the HIV treatment
guidelines issued by the NACP of Tanzania were
authorative for this cohort. The revision published in
2005 [10] advocated a standard regimen of d4T/3TC/
NVP and offered AZT/3TC/NVP, AZT/3TC/EFV as well
as d4T/3TC/EFV as alternatives in case of contraindica-
tions. In February 2009 [9], the preferred regimen was
changed to AZT/3TC/EFV with d4T/3TC/NVP and
TDF/FTC/EFV as alternative options. However, chan-
ging existing stavudine based prescriptions was only ad-
vocated in case of serious side effects. Stavudine was
explicitly contraindicated for subjects initiating cART
only in the latest revision being issued in 2012 [11],
which was after the period analyzed in this study.
As depicted in Figure 2a, the percentage of patients
initiated on stavudine containing regimens decreasedFigure 2 Line graphs of usage of cART regimens by calendar year. a)
Absolute count of patients being prescribed particular cART drug combinaquickly from a maximum of 71% in 2008 to 11% within
the following three years. This scale down conformed to
the changed NACP guidelines issued in 2009 and was
compensated mostly by increasing prescriptions of AZT/
3TC/NVP and TDF/FTC/EFV. Within three years, the
new generic fixed dose combination of TDF/FTC/EFV
became the most frequently prescribed combination in
patients initiating cART with a portion of more than
40% by the end of the study. It is notable that even be-
fore the WHO issued explicit recommendations against
usage of stavudine in 2010 and several years before the
NACP followed suit in 2012, prescriptions of stavudine
were decreasing importantly. This occurred supposedly
by making alternative regimens available to clinicians
observing stavudine-associated adverse events.
In contrast to the changes seen in first-line prescrip-
tions for patients initiating cART, stavudine based com-
binations were still the most used in the entire cohort by
the end of the year 2011. This observation is explained
by the fact that patients already receiving stavudine from
earlier years on are not changed to more modern combi-
nations in the absence of obvious severe side effects. InProportions of initial first-line regimens prescribed by calendar year. b)
tions overall by calendar year.
Table 3 Absolute count of patients being prescribed particular cART drug combinations overall by calendar year
2007 2008 2009 2010 2011
(n = 636) (n = 1274) (n = 1758) (n = 1787) (n = 1846)
d4T/3TC/NVP 456 (71.7%) 955 (74.9%) 1080 (61.4%) 826 (46.2%) 674 (36.5%)
d4T/3TC/EFV 62 (9.7%) 105 (8.2%) 132 (7.5%) 81 (4.5%) 65 (3.5%)
AZT/3TC/NVP 11 (1.7%) 71 (5.5%) 92 (5.2%) 150 (8.4%) 297 (16%)
AZT/3TC/EFV 217 (34.1%) 370 (29%) 654 (37.2%) 609 (34%) 641 (34.7%)
TDF/FTC/EFV 0 0 84 (4.8%) 431 (24.1%) 600 (32.5%)
ABC/ddI/LPV/r / ABC/ddI/SQV/r 6 (0.95%) 18 (1.4%) 18 (1%) 22 (1.2%) 33 (1.7%)
Data is presented as count (column percentage). In case of >1 regimen per year per patient, multiple counts per patients were included in one year. Total number
(n) represents sum of patients per year, not sum of regimen counts listed. Column percentages were denominated using n.
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underwent a substitution to another first-line combin-
ation during the period of observation. However, this ap-
proach was according to the national guidelines valid for
the duration of the study. The WHO recommended ex-
changing stavudine for alternative regimens from their
2010 guidelines on [1], but acknowledged that this op-
tion was limited by cost concerns in low-income
settings. Thus far, only few national guidelines in Sub-
Saharan African countries, e.g. in Botswana [12], specif-
ically advocated replacing stavudine also in patients not
experiencing side effects. Such an approach is sensible
and should be sought, as lipodystrophy and peripheral
neuropathy develop progressively, even after six years
on treatment [2,13]. In 2013, governmental agencies in
Tanzania adopted the phasing out of stavudine by com-
pletely ceasing the supply of stavudine. A newly available
fixed dose combination of tenofovir, lamivudine, and efa-
virenz is now the preferred recommended first line regi-
men in Tanzania, and AZT-based combinations have
been used as alternative first line regimens.
The WHO published results of their international
antiretroviral drug survey in low- and middle-income
countries in the HIV report in 2011 [14]. In summary
statistics of 14 countries in SSA and India, stavudine
based cART constituted the most commonly used one
overall, decreasing from a portion of 67% in 2006 to 43%
of all regimens in 2010. The decline of the usage of stav-
udine started two years earlier than in this Tanzanian
cohort but prescriptions eventually reached similar
levels by 2010. The WHO data showed an increase ofTable 4 Subsequent regimens in case a stavudine containing
combination
2007 2008
(n = 18) (n = 46)
AZT/3TC/NVP 2 (11.1%) 22 (47.8)
AZT/3TC/EFV 16 (88.9%) 24 (52.2%)
TDF/FTC/EFV 0 0
Data is presented in counts (column percentage). In case of >1 regimen per year pe
(n) represents sum of patients per year, not sum of regimen counts listed.prescriptions of TDF-based combinations attaining 15%
of total prescriptions by the end of 2010, which is less
pronounced than seen in this cohort. However, the
WHO presented aggregate data of several countries
which does not allow drawing conclusions about trends
in individual settings.
TDF/FTC/EFV was less frequently prescribed to
women than to men in this cohort. This difference was
compensated by a higher rate of prescriptions of d4T/
3TC/NVP and AZT/3TC/NVP to female patients. Be-
cause of possible teratogenic effects in the first trimester
of pregnancy [15], usage of efavirenz was generally not
recommended in women of childbearing age [9]. Thus, a
lower frequency of regimens containing efavirenz com-
pared to nevirapine as the non-nucleoside reverse tran-
scriptase inhibitor component is plausible. However, it is
unclear, why no difference of gender concerning pre-
scriptions of the default regimen AZT/3TC/EFV has
been observed.
The rate of patients receiving a second line combin-
ation was low (maximum of 1.7% in 2011) when com-
pared to expected therapeutic failure rates [16] which
might indicate problems in managing of suspected treat-
ment failure cases. In this cohort, no HIV-1 viral load
measurements were available in order to assess eligibility
for second line treatment. This lack likely resulted in a
less sensitive and specific diagnosis of treatment failure.
Proposed prohibitive factors for prescription of second
line regimens are distrust against immunological treat-
ment failure criteria and concerns of lack of therapeutic
alternatives once second line treatment is initiated [17].regimen was substituted with another first line
2009 2010 2011
(n = 66) (n = 69) (n = 43)
23 (34.8%) 32 (46.4%) 18 (41.9%)
30 (45.5%) 6 (8.7%) 3 (7%)
13 (19.7%) 31 (44.9%) 22 (51.1%)
r patient, multiple counts per patients are included in one year. Total number
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rate of patients lost to follow-up, individual follow-up
times are short given the overall five year study period,
which limits the value of statements about trends in long
term therapy. Reasons for treatment modifications were
not recorded in a standardized manner. This flaw limits
causal analysis of prescription dynamics, particularly
those associated with side effects of stavudine.
Conclusions
Updated guidelines and modern pharmaceuticals have
been adopted efficiently in this Tanzanian cohort. Consist-
ent with these, the general usage of stavudine remained
very substantial still in 2011: It declined to low levels in
antiretroviral combinations of patients initiating cART.
However, the majority of subjects being prescribed stavu-
dine primarily in earlier years are not changed to more
modern combinations.
Monitoring of drug prescriptions is a simple and feas-
ible approach to identify deficits in implementation of
treatment guidelines.
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